China Sees Increasing Appetite For Innovative Products – PharmAsia Summit
This article was originally published in PharmAsia News
China's life sciences industry is at a crossroads, and new commercial models are needed to drive future growth, but a disconnect between corporate strategies may derail execution.
You may also be interested in...
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.